Tonix Pharmaceuticals Reports Positive Phase 1 Results for TNX-1500

Tonix Pharmaceuticals has announced encouraging results from its Phase 1 trial of TNX-1500, an Fc-modified humanized anti-CD40L monoclonal antibody designed to prevent organ transplant rejection and treat autoimmune diseases. Conducted in healthy participants, the study assessed TNX-1500’s safety, tolerability, pharmacokinetics, and pharmacodynamics, with results supporting its next-stage development. The therapy was well-tolerated, and data suggest it could offer improved activity and safety compared to first-generation anti-CD40L therapies, which were previously limited by thrombosis risks.

Dr. Seth Lederman, CEO of Tonix, emphasized the need for safer and more effective transplant rejection treatments, noting that TNX-1500 was engineered to preserve therapeutic benefits while enhancing safety. Chief Medical Officer Dr. Gregory Sullivan added that the trial’s pharmacokinetic data support a monthly dosing regimen, with TNX-1500 successfully blocking antibody responses at 10 mg/kg and 30 mg/kg doses. With these promising results, Tonix is now preparing to launch a Phase 2 efficacy study, aiming to improve long-term transplant success while reducing toxicity risks.